Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAinPD: Noradrenergic System in PD Nonmotor Symptoms
NCT04346394Phase 1Withdrawn
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yohimbine in Parkinson's disease (PD). Primary endpoint: Difference in fatigue at 6 months. Planned start May 2021; status: withdrawn.
02
Drugs
yohimbine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04346394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346394.